cebranopadol cebranopadol cebranopadol (developmental code grt-6005) is an opioid analgesic of the benzenoid class which is currently under development internationally by grünenthal, a german pharmaceutical company, and its partner depomed, a pharmaceutical company in the united states, for the treatment of a variety of different acute and chronic pain states. as of november 2014, it is in phase iii clinical trials. cebranopadolclinical dataroutes ofadministrationoralatc codenonepharmacokinetic dataelimination half-life~4.5 hoursidentifiers iupac name (1r,4r)-6’-fluoro-n,n-dimethyl-4-phenyl-4’,9’-dihydro-3’h-spiroindol]-4-amine cas number863513-91-1pubchem cid11848225drugbankdb12830chemspider29398942unii7gdw9s3gn3keggd10436chemical and physical dataformulac24h27fn2omolar mass378.491 g·mol−13d model (jsmol)interactive image smiles cn(c)1(c2ccccc2)cc2(cc1)occc1c2c2ccc(f)cc12 inchi inchi=1s/c24h27fn2o/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26h,10-15h2,1-2h3/t23-,24-key:csmvozkewsofer-rqnojgixsa-n cebranopadol is unique in its mechanism of action as an opioid, binding to and activating all four of the opioid receptors; it acts as a full agonist of the μ-opioid receptor (ki = 0.7 nm; ec50 = 1.2 nm; ia = 104%), and δ-opioid receptor (ki = 18 nm; ec50 = 110 nm; ia = 105%), and as a partial agonist of the nociceptin receptor (ki = 0.9 nm; ec50 = 13.0 nm; ia = 89%) and κ-opioid receptor (ki = 2.6 nm; ec50 = 17 nm; ia = 67%). the ec50 values of 0.5–5.6 µg/kg when introduced intravenously and 25.1 µg/kg after oral administration. cebranopadol shows highly potent and effective antinociceptive and antihypertensive effects in a variety of different animal models of pain. notably, it has also been found to be more potent in models of chronic neuropathic pain than acute nociceptive pain compared to selective μ-opioid receptor agonists. relative to morphine, tolerance to the analgesic effects of cebranopadol has been found to be delayed (26 days versus 11 days for complete tolerance). in addition, unlike morphine, cebranopadol has not been found to affect motor coordination or reduce respiration in animals at doses in or over the dosage range for analgesia. as such, it may have improved and prolonged efficaciousness and greater tolerability in comparison to currently available opioid analgesics. as an agonist of the κ-opioid receptor, cebranopadol may have the capacity to produce psychotomimetic effects, dysphoria, and other adverse reactions at sufficiently high doses, a property which could potentially limit its practical clinical dosage range, but would likely reduce the occurrence of patients taking more than their prescribed dose.